GT Biopharma Company Insiders

GT Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.5418) % which means that it has lost $0.5418 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0494) %, meaning that it created substantial loss on money invested by shareholders. GT Biopharma's management efficiency ratios could be used to measure how well GT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/11/2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -1.91. At this time, GT Biopharma's Total Current Liabilities is relatively stable compared to the past year. As of 06/11/2024, Change To Liabilities is likely to grow to about 8.5 M, while Liabilities And Stockholders Equity is likely to drop slightly above 13.2 M. As of 06/11/2024, Common Stock Shares Outstanding is likely to drop to about 1.3 M. In addition to that, Net Loss is likely to drop to about (54.8 M)

GT Biopharma Workforce Comparison

GT Biopharma Insider Trading History

GT Biopharma Notable Stakeholders

The success or failure of an entity such as GT Biopharma often depends on how effective the management is. GT Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GTBP management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GTBP management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in GT Biopharma's official financial statements typically reflect GT Biopharma's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving GT Biopharma's quantitative information. For example, before you start analyzing numbers published by GTBP accountants, it’s essential to understand GT Biopharma's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.

Please note, the imprecision that can be found in GT Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GT Biopharma. Check GT Biopharma's Beneish M Score to see the likelihood of GT Biopharma's management manipulating its earnings.

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.